Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block

Expert Review of Neurotherapeutics

Volumn 9, Issue 5, 2009, Pages 599-608

  Hogg, Rosemary M G ^a   Mirakhur, Rajinder K ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Anticholinesterase; Cyclodextrin; Neostigmine; Neuromuscular block; Sugammadex

Indexed keywords

ATROPINE; CISATRACURIUM; FLUCLOXACILLIN; FUSIDIC ACID; GLYCOPYRRONIUM BROMIDE; ISOQUINOLINE DERIVATIVE; NEOSTIGMINE; PANCURONIUM; PROGESTERONE; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; TOREMIFENE; VECURONIUM;

BRONCHOSPASM; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSGEUSIA; ENCAPSULATION; GROUPS BY AGE; HEART DISEASE; HEART RATE; HUMAN; HYPOTENSION; KIDNEY DISEASE; LUNG DISEASE; MOLECULE; NAUSEA AND VOMITING; NEUROMUSCULAR BLOCKING; OBESITY; RECOMMENDED DRUG DOSE; REVIEW; SECRETIONS; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLODEXTRINS; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR DISEASES; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 66249104339     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.22     Document Type: Review

References (74)

1. Griffith HR, Johnson GE. The use of curare in general anesthesia.Anesthesiology3, 418-420 (1942).
2. A historical pAβer describing the first use of muscle relaxants in patients.
3. Gray TC. D-tubocurarine chloride.Proc. R Soc. Med.41, 559-568 (1948).
4. Foldes FF. The impact of neuromuscular blocking agents on the development of anesthesia and surgery. In:Muscle Relaxants (SecondEdition).Agoston S, Bowman WC (Ed.), Elsevier, Amsterdam-New York-Oxford 1-17 (1990).
5. Durant NN, Katz RL. Suxamethonium.Br.J. Anesth.54, 195-208 (1982).
6. Bowman WC. Neuromuscular block.Br. J. Pharmacol.147(Suppl. 1), S277-S286 (2006).
7. McCourt KC, Salmela L, Mirakhur RKet al.Comparison of rocuronium and suxamethonium for use during rAβid sequence induction of anesthesia.Anesthesia53, 867-871 (1998).
8. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.Anesthesiology98, 1042-1048 (2003).
9. Large study highlighting the variability in the duration of action of neuromuscular blocking agents.
10. Claudius C, Karacan H, Viby-Mogensen J. Prolonged residual paralysis after a single intubating dose of rocuronium.Br. J. Anesth.99, 514-517 (2007).
11. Eikermann M, Zarembal S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.Br. J. Anes.101, 344-349 (2008).
12. Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology57, 261-266 (1982).
13. Magorian TT, Lynam DP, Caldwell JE, Miller RD. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology73, 410-414 (1990).
14. Van den Broek L, Proost JH, Wierda JM. Early and late reversibility of rocuronium bromide.Eur. J. Anesthesiol.11, 128-132 (1994).
15. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate acting neuromuscular blocking drugs.Anesthesia56, 312-318 (2001).
16. Berg H, Roed J, Viby-Mogensen Jet al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium.Ada Anesthesiol. Scand.41, 1095-1103 (1997).
17. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiogrAβhy and simultaneous manometry after atracurium.Anesthesiology92, 977-984 (2000).
18. Murphy GS, Szokol JW, Marymont JHet al. Intraoperative acceleromyogrAβhic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit.Anesthesiology109, 389-398 (2008).
19. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.Anesth. Analg.107, 130-137 (2008).
20. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical Aβplications.Int. J. Pharm.329, 1-11 (2007).
21. Full of information regarding the use of cyclodextrins in medicine.
22. Challa R, Ahula A, Ali Jet al.Cyclodextrins in drug delivery: an updated review.AAβS Pharma. Sci. Tech.6, 329-357 (2005).
23. Comprehensive review of the pharmacology of cyclodextrins.
24. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice.Int. J. Pharm.225, 15-30 (2001).
25. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers.Adv. Drug Deliv. Rev.59, 645-666 (2007).
26. Reports the use of cyclodextrins in medicine.
27. Zhang M-Q. Drug-specific cyclodextrins: the future of rAβid neuromuscular block reversal?Drugs Future!?,,347-354 (2003).
28. Discussion on the use of modified y-cyclodextrins for use in reversal of neuromuscular block.
29. Bom A, Bradley M, Cameron K. A novel concept of reversing neuromuscular block: chemical encAβsulation of rocuronium bromide by a cyclodextrin-based synthetic host.Angew. Chem. Int. Ed. Engl.41, 266-270 (2002).
30. One of the first publications examining the concept of the use of cyclodextrins and their modifications for use in reversal of neuromuscular block.
31. Adam JM, Bennett DJ, Bom Aet al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J. Med. Chem.45, 1806-1816 (2002).
32. Booij LHDJ. Cyclodextrins and the emergence of sugammadex.Anesthesia64 (Suppl. 1), 31-37 (2009).
33. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969. A novel agent to reverse the action of rocuronium bromide.Anesthesiology103, 695-703 (2005).
34. Report of the first use of sugammadex (known as Org 25969 at that time) in humans.
35. Sorgenfrei IF, Norrild K, Larsen PBet al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose finding and safety study.Anesthesiology104, 667-674 (2007).
36. Sparr HJ, Vermeyen KM, Beaufort AMet al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology106, 935-943 (2007).
37. De Boer HD, van Egmond J, Marcus M, Schouten P, Smeets J, Driessen JJ. Pharmacokinetics of high doses of the selective relaxant binding agent sugammadex, administered shortly after profound rocuronium-induced neuromuscular block.Eur. J. Anesthesiol.23(Suppl. 37), 143 (2006)
38. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.Anesthesiology99, 632-637 (2003).
39. Epemolu O, Mayer I, Hope F, Scullion P, Desmond P. Liquid chromatogrAβhy/mass spectrometric bioanalysis of a modified y-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its Aβplication to determine the plasma pharmacokinetics of Org 25969.RAβid Commun. Mass Spectrom.16, 1946-1952 (2002).
40. Naguib M. Sugammadex: another milestone in neuromuscular pharmacology.Anesth. Analg.104, 575-581 (2007).
41. Discussion of how sugammadex may change practice.
42. Staals LM, Snoek MJ, Driessen JJ, Flockton E, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.Br.J. Anesth.101, 492-497 (2008).
43. Hartman J, Smeets JMW, deZwart MAH, Peters SMA.In-vitrodialysability of sugammadex (Org 25969), a selective relaxant binding agent for reversal of neuromuscular block induced by rocuronium.Eur. J. Anesthesiol.26(Suppl. 37), 144 (2006).
44. Mason R, Bom A. Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBAs in anesthetized guinea pigs.Eur. J. Anesthesiol.18, 100 (2001).
45. Bom A, Mason R, Mclndewar I. Org 25969 causes rAβid reversal of rocuronium-induced neuromuscular block, independent of acid-base status.Anesthesiology96, (2002) (Abstract A-1009).
46. Bom A, Van Egmond J, Hope Fet al. RAβid reversal of rocuronium induced neuromuscular block by Org 25969 is independent of renal perfusion.Anesthesiology99 (2003) (Abstract A-1158).
47. De Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anesthetized Rhesus monkey.Br. J. Anesth.96, 473-479 (2006).
48. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment.Anesthesiology98, 1037-1039 (2003).
49. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.Anesthesiology98, 1042-1048 (2003).
50. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision.Acta Anesth. Scand.51, 789-808 (2007).
51. Piihringer F, Blaszyk M, Gammu G, Sparr H, Heeringa M. Sugammadex achieves fast recovery from shallow neuromuscular blockade induced by rocuronium or vecuronium: dose-response studies.Eur. J. Anesthesiol.24(Suppl. 39), 111 (2007).
52. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WGF. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.Anesthesiology106, 283-288 (2007).
53. Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 ug/kg). Eur. J. Anesthesiol.24(Suppl. 39), 125-126 (2007).
54. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.Brit. J. Anes.96, 36-43 (2006).
55. Groudine SB, Soto R, Lien C, Drover D, Roberts K. Randomised, dose finding, Phase 2 study of the selective relaxant binding drug, sugammadex, cAβable of safely reversing profound rocuronium-induced neuromuscular block.Anesth. Analg.104, 555-562 (2007).
56. Duvaldestin P, Kuizenga K, Kjaer CC, Saldieen V, Debaene B. Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose response study. Eur. J. Anesthesiol.24(Suppl. 39), 123 (2007).
57. Puhringer FK, Rex C, Sielenkamber AWet al. Reversal of profound, high dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. An international multicenter, randomised, dose finding, safety assessor-blinded, Phase 2 trial.Anesthesiology109, 188-197 (2008).
58. De Boer HD, Driessen JJ, Marcus MAE, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex.Anesthesiology107, 239-244 (2007).
59. Lee C, Jahr JS, Candiotti K, Warriner B, Zornow M. Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology107, A988 (2007).
60. Alvarez-Gomez JA, Wattwil M, Vanacker B, Lora-Tamayo JI, Khunl-Brady KS. Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Eur. J. Anesthesiol.24(Suppl. 39), 124-125 (2007).
61. Jones RK, Caldwell JE, Brull S, Soto R. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.Anesthesiology109, 816-824 (2008).
62. Lemmens HJM, El-Orbany M, Berry J, Martin G. Sugammadex reverses profound vecuronium blockade more rAβidly than neostigmine. Anesthesiology107, A1578 (2007).
63. Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex.Anesth. Analg.104, 582-584 (2007).
64. McDonagh DL, Benedict PE, Kovac ALet al. Safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology107, A1583 (2007).
65. Plaud B, Meretoja O, Hofmockel Ret al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.Anesthesiology110, 284-294 (2009).
66. Dahl V, Pendeville PE, Hollman MWet al. Reversal of rocuronium induced blockade by sugammadex in cardiac patients.Anesthesiology107, A1581 (2007).
67. Amao R, Zornow MH, Cowan MRet al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology107, A1582 (2007).
68. Monk TG, Rietbergen H, Woo T. Obesity has no clinically relevant impact upon recovery time following administration of sugammadex. Anesthesiology109, A682 (2008).
69. De Kam P-J, van Kuijk J, Smeets Jet al. Single IV sugammaedx doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology107, A1580 (2007).
70. Cammu G, De Kam PJ, Demeyer Iet al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.Br. J. Anesth.100, 373-379 (2008).
71. Plaud B, van Heumen E, Zweirs A. Sugammadex is well tolerated for the reversal of rocuronium or vecuronium induced neuromuscular blockade in a pooled analysis of adverse events in 10 placebo controlled trials.Eur. J. Anesthesiol.24(Suppl. 39), 111 (2007).
72. Mirakhur RK, McCarthy GJ. Basic pharmacology of reversal agents.Anesthesiol. Clin.11, 237-250 (1993).
73. Review of the pharmacology of anticholinesterase agents.
74. Bom A, Hope F. Neuromuscular block induced by rocuronium and reversed by the encAβsulating agent Org 25969 can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium.Eur. J.Anesthesiol.22(Suppl. 34), 120(2005).